Current Report Filing (8-k)
July 08 2022 - 4:06PM
Edgar (US Regulatory)
0001680139
false
0001680139
2022-07-05
2022-07-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d) of the
Securities Exchange
Act of 1934
Date of Report (Date of
earliest event reported): July 5, 2022
HealthLynked Corp.
(Exact name of registrant
as specified in charter)
Nevada |
|
000-55768 |
|
47-1634127 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
1265 Creekside
Parkway, Suite 302, Naples FL 34108
(Address of principal executive offices)
(800)
928-714
(Registrant’s telephone
number, including area code)
N/A
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section 12(b)
of the Act: None.
Item 1.01 Entry into a Material Definitive Agreement.
On July 5, 2022, HealthLynked
Corp. (the “Company”) entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, Ltd. (“Yorkville”).
Pursuant to the SEPA, the Company shall have the right, but not the obligation, to sell to Yorkville up to 30,000,000 of its shares of
common stock, par value $0.0001 per share, at the Company’s request any time during the commitment period commencing on July 5,
2022 and terminating on the earliest of (i) the first day of the month following the 36-month anniversary of the SEPA and (ii) the date
on which Yorkville shall have made payment of any advances requested pursuant to the SEPA for shares of the Company’s common stock
equal to the commitment amount of 30,000,000 shares of common stock. Each sale the Company requests under the SEPA (an “Advance”)
may be for a number of shares of common stock with an aggregate value of up to greater of: (i) an amount equal to thirty percent (30%)
of the aggregate daily volume traded of Common Shares on the Company’s Principal Market for the three (3) Trading Days immediately
preceding an Advance Notice, or (ii) 2,000,000 shares of common stock. The shares would be purchased at 96.0% of the Market Price (as
defined below) and would be subject to certain limitations, including that Yorkville could not purchase any shares that would result in
it owning more than 4.99% of the Company’s outstanding common stock at the time of an Advance (the "Ownership Limitation").
“Market Price” is defined in the SEPA as the average of the VWAPs (as defined below) during each of the three consecutive
trading days commencing on the trading day following the Company’s submission of an Advance notice to Yorkville. “VWAP”
is defined in the SEPA to mean, for any trading day, the daily volume weighted average price of the Company’s common stock for such
date on the Principal Market (as defined below) as reported by Bloomberg L.P. during regular trading hours. “Principal Market”
is defined in the SEPA as the New York Stock Exchange, the Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market,
OTC Markets’ OTCQB Market, or the NYSE Euronext, whichever is at the time the principal trading exchange or market for the Common
Shares.
Pursuant to the SEPA,
the Company (i) is required to register all shares which Yorkville may acquire and file with the Securities and Exchange Commission
an effective shelf registration statement on Form S-1 (the “Registration Statement”), registering the shares of Common
Stock that are to be offered and sold to Yorkville pursuant to the SEPA along with the Commitment Shares (as defined below), and
(ii) currently intends to use the net proceeds from any sale of the shares for working capital and other general corporate purposes.
As consideration for Yorkville’s commitment to purchase shares of common stock at our direction upon the terms and subject to
the conditions set forth in the SEPA, upon execution of the SEPA, we issued to Yorkville 895,255 shares of Common Stock pursuant to
the terms of the SEPA (the “Commitment Shares”), and (2) paid Yorkville’s structuring and due diligence fees of
$10,000.
Furthermore, the Company entered into a Note Purchase Agreement dated July 5, 2022 (the “Note Agreement”) pursuant to which,
within three business days after the effectiveness of the Registration Statement, the Company may request that Yorkville enter into a promissory note (“Promissory Note”) in an amount up to $550,000.
The Promissory Note will mature on the six-month anniversary of execution. The Promissory Note accrues interest at a rate of 0%, but will
be issued with 5% original issue discount, and will be repaid in 5 equal monthly installments beginning on the 30th day following the
date of the Promissory Note’s execution. The Promissory Note may be repaid with the proceeds of an Advance under the Purchase Agreement or repaid
in cash and, if repaid in cash, together with a 2% premium.
The foregoing is a summary
description of certain terms of the SEPA and Note Purchase Agreement. For a full description of all terms, please refer to the copies
of the SEPA and the Note Purchase Agreement that are filed herewith as Exhibit 10.1 and Exhibit 10.2 to this Current Report on Form 8-K
and is incorporated herein by reference.
This Current Report on Form
8-K shall not constitute an offer to sell or a solicitation of an offer to buy any shares of common stock, nor shall there be any sale
of shares of common stock in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or other jurisdiction.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits:
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the
undersigned hereunto duly authorized.
|
HEALTHLYNKED CORP. |
|
|
Date: July 8, 2022 |
/s/ George O’Leary |
|
George O’Leary |
|
Chief Financial Officer |
2
HealthLynked (QB) (USOTC:HLYK)
Historical Stock Chart
From Aug 2024 to Sep 2024
HealthLynked (QB) (USOTC:HLYK)
Historical Stock Chart
From Sep 2023 to Sep 2024